Although the significance of SGLT2 inhibitor-induced RAAS activation has not been clarified, it seems to be inconsistent with SGLT2 inhibitors’ capability of renoprotection, because type-1 angiotensin-II receptor (AT1R) activation plays an important role in the development of DN. Here, SLC5A2 is linked to liver dysplastic nodule.